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Abstract We have purified a form of protein phosphatase 1
(PP1) from HeLa cell nuclei, in which the phosphatase is
complexed to a regulatory subunit termed p99. We report here
the cloning and characterisation of the p99 component. p99
mRNA is widely expressed in human tissues and immuno-
fluorescence analysis with anti-p99 antibodies showed a punc-
tate nucleoplasmic staining with additional accumulations within
the nucleolus. The C-terminus of p99 contains seven RGG
RNA-binding motifs, followed by eleven decapeptide repeats
containing six or more of the following conserved residues
(GHRPHEGPGG), and finally a putative zinc finger domain.
Recombinant p99 suppresses the phosphorylase phosphatase
activity of PP1 by s 90% and the canonical PP1-binding motif
on p99 (residues 396^401) is unusual in that the phenylalanine
residue is replaced by tryptophan.
z 1997 Federation of European Biochemical Societies.
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1. Introduction
Protein phosphatase 1 (PP1), one of the major serine/threo-
nine-speci¢c protein phosphatases of eukaryotic cells, is con-
trolled by accessory proteins termed targetting subunits, that
regulate its substrate speci¢city, determine its subcellular lo-
calisation and confer the ability to be regulated by extracel-
lular signals [1]. A number of cytosolic targetting subunits
have been identi¢ed, of which the best characterised are those
that direct PP1 to glycogen and to myosin. A small peptide
from the glycogen-targetting subunit has been cocrystallised
with PP1 and the structure solved to 3 Aî resolution [2]. This
analysis revealed that the hexapeptide sequence Arg-Arg-Val-
Ser-Phe-Ala interacts with a small hydrophobic channel on
the surface of PP1 [2]. Similar Arg/Lys-Arg/Lys-Val/Ile-Xaa-
Phe sequences are present in many other PP1-targetting pro-
teins and, in the case of the myosin-targetting subunit [3] and
p53BP2 [2,4], there is direct evidence that this motif is likely to
be important in binding to PP1.
PP1 activity is not only present in the cytosol, but is also
located and even enriched in the nucleus [5,6] where it is likely
to regulate nuclear processes including pre-mRNA splicing
[7,8] and the cell division cycle [9^11]. Two major forms of
nuclear PP1 have been resolved by anion exchange chroma-
tography of rat nuclear extracts [12]. The species eluting at a
lower concentration of NaCl comprised PP1 complexed to a
41 kDa RNA-binding protein [13], which has been cloned,
characterised and termed NIPP1 (nuclear inhibitor of PP1)
because it prevents the dephosphorylation of a number of
substrates by PP1 [14,15]. The second major species of PP1
that eluted at a higher concentration of NaCl than the PP1-
NIPP1 complex was found to comprise PP1 complexed to a
PP1-binding protein of apparent molecular mass 111 kDa
[12].
We have previously identi¢ed a role for PP1 in the regula-
tion of pre-mRNA splicing [7,8]. To extend these analyses, we
have investigated proteins present in HeLa nuclear extracts
which interact strongly with PP1. Here we report the puri¢-
cation, cloning and characterisation of a novel human nuclear
PP1-binding protein that we term p99.
2. Materials and methods
2.1. Materials
HeLa cell nuclear extracts were purchased from Computer Cell
Culture Center (Mons, Belgium), DEAE-Sepharose from Pharmacia
(Milton Keynes, UK) and endoproteinase Glu-C from Boehringer
Mannheim (East Sussex, UK). The EST clone (Genbank accession:
R11639) encoding a fragment of p99 (residues 45^310) was provided
by U.K. HGMP Resource Centre (Cambridge, UK), and antibodies
against the protein encoded by R11639 were generated by the Scottish
Antibody Production Unit (Carluke, Ayrshire, UK). Microcystin-Se-
pharose was provided by Dr. Carol MacKintosh (MRC Protein Phos-
phorylation Unit, Dundee) and peptides were synthesised by Mr. F.B.
Caudwell (MRC Protein Phosphorylation Unit, Dundee) or by Dr.
Grahame Bloomberg (Department of Biochemistry, University of
Bristol, UK).
2.2. Puri¢cation of the p99-PP1 complex
HeLa cell nuclear extract was fractionated on an 8U5 cm column
of DEAE-Sepharose equilibrated with 20 mM HEPES pH 7.9, 0.1 M
KCl and 0.05% (by mass) Triton X-100 (Bu¡er A). The £ow-through
containing the NIPP1-PP1 complex was collected and the p99-PP1
complex was eluted with Bu¡er A containing 0.25 M KCl. The 0.25
M KCl eluate was then chromatographed on a 1.4U0.8 cm column of
microcystin-Sepharose [16]. The £ow-through was reapplied to the
column a second time to ensure that all of the p99-PP1 complex
was bound and, after washing with Bu¡er A, bound proteins were
eluted with Bu¡er A containing 3 M NaSCN.
2.3. Protein blotting analysis
Human PP1 (the Q1 isoform) [4] was labelled with digoxygenin
(DIG-PP1) and used in Far Western assays essentially as described
[17]. Proteins were separated by SDS-PAGE and transferred to nitro-
cellulose membranes using a semi-dry transfer apparatus. After trans-
fer, the ¢lters were blocked in 20 mM Tris/HCl pH 7.5, 150 mM NaCl
and 2% non-fat dry milk (w/v). The anti-R11639 serum was used at a
1:4000 dilution in the same bu¡er, while DIG-PP1 was used at 1 Wg/
ml of this bu¡er. The secondary antibodies from Pierce (Chester, UK)
were used according to the manufacturer’s recommendations.
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2.4. Construction of vectors for expression of proteins in E. coli
The DNA was cut out from the EST-R11639 clone using restriction
enzymes XhoI and HindIII, and subcloned into the same sites in
pRSET B (Invitrogen, NV Leek, The Netherlands). Complementary
oligonucleotides (5P-GGGATCCATGGGTTCGGGTCCCATAGAC-
CCCAAAGAACT-3P) and (5P-CAAGCTTAGAAAACCCCCAGG-
AACCCAAGCAAGTG-3P) to the clone Fb19 were synthesised which
incorporated BamHI and HindIII restriction sites. A p99 cDNA was
obtained using these oligonucleotides in a PCR ampli¢cation with
HeLa cell poly(A)+cDNA. A DNA fragment of the expected
size was isolated, cleaved with BamHI and HindIII and cloned
into the same restriction sites in expression vector pRSET A (In-
vitrogen).
2.5. Expression of proteins in E. coli and their puri¢cation
p99 and its fragments expressed from pRSET vectors contain an
additional 36 residues at their N-termini which include a hexahistidine
tag for a⁄nity puri¢cation on nickel-nitrilotriacetate and an enter-
okinase recognition site. All p99 constructs were transformed into
E. coli AD494 (DE3) pLys S cells. Single colonies were grown at
37‡C in LB medium (1l) containing 0.1 mg/ml ampicillin (Sigma,
Poole, UK) to an A 595 nm of 0.5. Protein expression was induced
by the addition of IPTG (3 mM) for 3 h. Cells were harvested and
resuspended in 15 ml of 20 mM HEPES pH 7.9, 0.5 M NaCl con-
taining ‘complete’ proteinase inhibitor cocktail (Boehringer, one tablet
per 50 ml) (Bu¡er B) and 6 M guanidinium-HCl. The suspension was
sonicated, centrifuged for 25 min at 20 000Ug, and the supernatant
decanted and added to 2 ml of nickel-nitrilotriacetate agarose (QIA-
GEN, Sussex, UK) pre-equilibrated in Bu¡er B plus 6 M guanidi-
nium-HCl. After mixing end over end for 1 h, the suspension was
poured into a column, and the beads washed with the same bu¡er
containing 20 mM imidazole until no protein could be detected in the
eluate. The bound proteins were eluted with Bu¡er B plus 0.6 M
imidazole, dialysed against 20 mM HEPES pH 7.9, 50 mM KCl,
0.1% (by vol) 2-mercaptoethanol and stored in aliquots at 320‡C.
Human PP1K [18] and human PP1Q [4] were expressed and puri¢ed
as described.
2.6. Confocal microscopy
HeLa cells were grown on coverslips in Dulbecco’s modi¢ed Eagle’s
medium supplemented with 10% foetal calf serum and 100 U/ml pen-
icillin and streptomycin (Gibco BRL, Berlin, Germany). Cells were
washed in PBS and ¢xed for 10 min with 3.7% paraformaldehyde in
CSK bu¡er (10 mM PIPES pH 6.8, 100 mM NaCl, 300 mM sucrose,
3 mM MgCl2, 2 mM EDTA) at room temperature. Permeabilisation
was performed with 1% (by mass) Triton X-100 in CSK bu¡er for
15 min at room temperature. Immuno£uorescence staining using af-
¢nity puri¢ed polyclonal sheep antibodies to the p99 fragment (resi-
dues 45^310) and Texas Red or FITC conjugated anti-sheep sec-
ondary antibodies (Jackson Immunoresearch Laboratories, Stratech
Scienti¢c Ltd., UK) was performed as described [19]. Fluorescence
microscopy was carried out using the Zeiss LSM 410 Confocal Laser
Scanning Microscope with excitation wavelengths of 488 nm (FITC)
and 543 nm (Texas Red).
2.7. Assay of PP1
32P-labelled rabbit skeletal muscle phosphorylase (containing 1.0
mol phosphate per mol subunit) was prepared by phosphorylation
with phosphorylase kinase. PP1 was assayed by the dephosphoryla-
tion of phosphorylase (10 WM) as described [20].
3. Results and discussion
3.1. Puri¢cation of the PP1-interacting protein p99 from HeLa
cell nuclear extracts
Proteins in nuclear extracts from HeLa cells were separated
by SDS-PAGE, blotted on to a nitrocellulose membrane and
probed with digoxigenin-labelled PP1CQ (DIG-PP1) to identi-
fy putative PP1-binding proteins [17]. Using this technique, we
detected two major PP1-binding proteins with apparent mo-
lecular masses of 41 and 114 kDa (Fig. 1), similar to the
results obtained previously for rat liver nuclear extracts [12].
We infer that the 41 kDa protein was NIPP1 since it was
recognised by anti-NIPP1 antibodies (data not shown).
In order to purify the form of PP1 that was complexed to
the larger protein, we ¢rst chromatographed HeLa cell nu-
clear extracts on DEAE-Sepharose to resolve this species
from the PP1-NIPP1 complex (Fig. 1). The eluate containing
the larger interacting protein but not NIPP1 was then sub-
jected to a⁄nity chromatography on microcystin-Sepharose
(Section 2.2) which binds PP1 and PP2A (and hence the pro-
teins with which they interact) [16]. The microcystin-Sephar-
ose eluate contained six major protein staining bands, two of
which corresponded to the 114 kDa PP1-binding protein and
the catalytic subunit of PP1 (Fig. 1). A number of smaller
bands were not characterised further. These may either be
the result of proteolysis or alternatively could be subunits of
other phosphatases, such as PP2A.
The protein band of interest was cut out from the gel,
digested with endoproteinase Glu-C and, after chromatogra-
phy on a Vydac C18 column (Hesperia, CA, USA), ¢ve pep-
tides were sequenced. These sequences were then used to inter-
rogate protein databases which identi¢ed several expressed
sequence tags (ESTs) containing DNA sequences that could
potentially code for this protein. The longest of these
(R11639) had an open reading frame (ORF) of 266 residues
and included two of the peptides identi¢ed from the puri¢ed
protein sample. This fragment was expressed in E. coli, puri-
¢ed as a 38 kDa protein (Fig. 2A), and used to raise anti-
bodies in sheep. These antibodies speci¢cally recognised a
band in nuclear extracts that comigrated with the 114 kDa
band detected by DIG-PP1 labelling (Fig. 2A and B), estab-
lishing that EST-R11639 encodes a fragment of p99.
At this juncture, a cDNA sequence termed Fb19 was de-
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Fig. 1. Puri¢cation of p99 from HeLa cell nuclear extracts. Proteins
from the nuclear extract (NE), the DEAE £ow-through (FT) and
the 0.25 M KCl eluate (Eluate) were separated by SDS-PAGE and
transferred to nitrocellulose membranes. PP1-interacting proteins
were detected by probing the ¢lters with DIG-PP1. The eluate was
further puri¢ed using microcystin (MC)-Sepharose and bound mate-
rial eluted with 3 M NaSCN (Eluate), subjected to SDS-PAGE and
silver stained. The positions of p99, NIPP-1, PP1 and the marker
proteins glycogen phosphorylase (97 kDa), bovine serum albumin
(66 kDa), ovalbumin (43 kDa) and carbonic anhydrase (29 kDa)
are indicated.
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posited into Genbank which not only contained EST-R11639,
but also the remaining three peptides identi¢ed by protein
sequencing (Fig. 3). A cDNA corresponding to the ORF of
Fb19 was obtained by PCR ampli¢cation of HeLa cell poly-
(A)+cDNA and expressed in E. coli as a fusion protein with a
hexahistidine tag at the N-terminus. After puri¢cation, this
protein migrated on SDS-PAGE as a major protein staining
band (Fig. 2C) that was recognised by DIG-PP1, and which
had a slightly slower mobility than 114 kDa (Fig. 2B); this is
consistent with the 36 residue N-terminal extension of the
expressed protein (Section 2.5). The preparation also con-
tained a number of minor bands of lower molecular mass
(Fig. 2A and C) that were not recognised by DIG-PP1 (Fig.
2B), and which are probably proteolytic fragments. Taken
together, these results show that the Fb19 cDNA encodes a
protein that is either very similar or identical to the 114 kDa
PP1-interacting protein.
The Fb19 protein, hereafter termed p99, comprises 940 res-
idues with a predicted molecular mass of 99 kDa, and no
obvious homologies with other protein sequences have been
detected. The initiating methionine is followed by a glycine
residue, suggesting that during translation the methionine is
removed and that the glycine is likely to become myristylated.
The presence of myristyl groups and other potential post-
translational modi¢cations, such as phosphorylation, could
explain why endogenous p99 migrates with an apparent mo-
lecular mass of 114 kDa. Sequence analysis also shows ¢ve
consecutive basic amino acids between residues 157^161 and
306^310 and six basic amino acids over the sequence between
residues 391^397, some of which may play a role in nuclear
import by acting as nuclear localisation signals [23]. The C-
terminal half of the molecule is extremely rich in glycine and
proline residues and there are seven Arg-Gly-Gly boxes be-
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Fig. 2. Identi¢cation of clone Fb19 as full-length p99. A: Nuclear extract (NE), Fb19 protein expressed in E. coli and puri¢ed on nickel-nitrilo-
triacetate agarose (Fb19) and the fragment of p99 encoded by EST-R11639 (R11639) were separated by SDS-PAGE, transferred to nitrocellu-
lose and probed with the anti-R11639 antibody. B: The ¢lter from A was stripped and reprobed with DIG-PP1. C: Coomassie blue-stained gel
showing the Fb19 protein after puri¢cation from E. coli extracts.
C
Fig. 3. The amino acid sequence of p99 and its expression pattern
in human tissues. A: The protein sequence of Fb19 is shown using
the one-letter code for amino acids. The sequences of the endopro-
teinase Glu-C generated proteolytic fragments of p99 are underlined
and the PP1-binding motif is shown in boldface type. The RGG re-
peats at the C-terminus are boxed. B: Alignment of the seven highly
conserved decapeptide repeats and the four imperfect repeats be-
tween residues 750 and 898 of p99. C: Northern blot analysis of
various human tissues. Each lane contains 2 Wg of poly(A)+RNA
isolated from the indicated tissues. The blot was hybridised with a
PstI DNA fragment from EST R11639 as probe (corresponding to
nucleotides 833^1316 of Fb19 cDNA).
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tween residues 674 and 740 (boxed in Fig. 3A). Such repeats
have been shown to mediate RNA binding in other proteins
[21]. These are followed almost immediately by seven deca-
peptide repeats between residues 750 and 850 and then by
four further variants of the decapeptide repeat. The repeat
motif is Gly-His-Arg-Pro-His-Glu-Gly-Pro-Gly-Gly, as shown
in the alignment in Fig. 3B. The extreme C-terminus (residues
912^931) contains a putative zinc ¢nger of the Cys-(Xaa)8-
Cys-(Xaa)5-Cys-(Xaa)3-His type. This motif has been shown
to bind zinc in vitro and is frequently repeated in such zinc-
binding proteins [22].
3.2. Tissue distribution of p99 mRNA
We next investigated the expression pattern of p99 mRNA
in di¡erent cell types by Northern blot hybridisation. A major
4.5 kb mRNA species was detected in all tissues examined
(Fig. 3C), consistent with the size of the Fb19 cDNA depos-
ited to Genbank. In heart and skeletal muscle, a minor 1.3 kb
band also hybridised with the p99 cDNA probe (Fig. 3C,
lanes 1 and 6). This smaller mRNA could result from alter-
native RNA processing and/or usage of another transcription
initiation site.
3.3. p99 is predominantly localised to the cell nucleus and
expressed in a wide range of tissues
Although p99 was puri¢ed from HeLa cell nuclear extracts,
the possibility that this protein is present in the cytoplasm as
well as the nucleus had not been excluded. To determine the
subcellular localisation of p99, HeLa cells were labelled for
indirect immuno£uorescence with the a⁄nity puri¢ed anti-
R11639 antibody and Texas Red conjugated anti-sheep sec-
ondary antibodies (Fig. 4). This showed a punctate nucleo-
plasmic staining pattern including several bright nucleoplas-
mic bodies per nucleus. Additional labelling was detected
within the nucleoli of these cells. Preincubation of the anti-
body with the p99 fragment encoded by EST-R11639 resulted
in the loss of staining (data not shown). The labelling pattern
con¢rmed that p99 is a nuclear protein and further suggests
that its function may be localised to discrete areas of the
nucleus.
3.4. Interaction of expressed p99 with PP1 in vitro
p99 was found to inhibit the phosphorylase phosphatase
activity of PP1Q (Fig. 5) and PP1K (data not shown). The
concentration required for 50% inhibition was similar to the
concentration of PP1 in the assays, demonstrating a stoichio-
metric interaction between the two proteins (Fig. 5). p99 sup-
pressed PP1 activity by s 90%, similar to the e¡ect of NIPP1
under the same conditions (data not shown). The fragment of
p99 (residues 45^310) encoded by EST-R11639, which did not
interact with DIG-PP1 (Fig. 2B), had no e¡ect on PP1 activity
(Fig. 5).
The observation that residues 45^310 of p99 do not interact
with PP1 raised the question of where the PP1-binding site
was located. Many PP1 modulators from all eukaryotic cells
share a common motif with a consensus sequence comprising
two or more basic residues lying just N-terminal to a Val/Ile-
Xaa-Phe sequence [2]. In the case of the glycogen-targetting
subunit, this motif has been shown to interact with a small
hydrophobic channel on the surface of PP1 [2]. However,
inspection of the amino acid sequence of p99 did not initially
reveal such a motif, suggesting that p99 might interact with a
di¡erent region of PP1. In order to investigate this question,
we incubated the p99-PP1 complex with a 32 residue peptide
from the PP1-binding protein p53BP2 which contains a ‘can-
onical’ PP1-binding motif. This peptide has been shown pre-
viously to disrupt the interaction between PP1 and its glyco-
gen-targetting and myosin-targetting subunits [2]. The peptide
from p53BP2 also disrupted the interaction between p99 and
PP1, as shown by a dose-dependent increase in the phospho-
rylase phosphatase activity of the p99-PP1 complex (Fig. 6A).
In contrast, a 16 residue peptide from NIPP1 that lies outwith
the putative PP1-binding site (residues 175^190) did not reac-
tivate the p99-PP1 complex (Fig. 6A). These observations
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Fig. 4. Confocal image of paraformaldehyde ¢xed, Triton X-100 permeabilised HeLa cells stained with a⁄nity puri¢ed sheep polyclonal anti-
body to the EST-R11639 fragment of p99 and Texas Red conjugated anti-sheep IgG secondary antibody. As shown, the nuclear staining pat-
tern is punctate, with increased labelling at discrete nucleoplasmic bodies (arrows) and additional accumulations within the nucleoli (arrow-
heads).
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suggested that p99 interacts with the same (or at least an
overlapping) region of PP1 as other targetting subunits.
In order to narrow down the site(s) of interaction between
p99 and PP1, we expressed a fragment of p99 encompassing
residues 1^675 and found that it bound to DIG-PP1 (data not
shown). Taken together with lack of binding of the fragment
encoded by EST-R11639 (residues 45^310), this suggested that
the binding site was either located in the ¢rst 45 residues from
the N-terminus or between residues 310 and 675.
While we could ¢nd no match to the consensus within the
¢rst 45 residues, the region between residues 310 and 675
contains a sequence Arg-Lys-Ser-Val-Thr-Trp (residues 396^
401) which is similar to the PP1-binding motif of other target-
ting subunits. The major di¡erence is the substitution of a
tryptophan for the phenylalanine that is conserved in this
motif in all other PP1-targetting subunits analysed to date.
At this juncture, we learned at the EMBO/FEBS workshop
on Protein Phosphatases (September 28th 1997) that Angus
Nairn and coworkers had cloned a rat protein that was highly
homologous to human p99. These investigators had found a
similar variation of the PP1-binding motif and established by
mutagenesis that the tryptophan was important for binding of
their protein to PP1 (Y.-G. Kwon, P. Allen, P. Greengard and
A.C. Nairn, manuscript in preparation). We therefore syn-
thesised a 16 residue peptide corresponding to residues 393^
408 of human p99 and showed that it could disrupt the p99-
PP1 complex, as indicated by an increase in phosphorylase
phosphatase activity (Fig. 6B). Changing Trp401 to Ala abol-
ished the ability of this peptide to disrupt the p99-PP1 com-
plex, whereas changing Trp401 to Phe had no e¡ect (Fig. 6B).
Taken together, these data indicate that residues 396^401 are
indeed critical for the interaction of p99 with PP1. p99 is the
¢rst PP1-binding protein in which the apparently invariant
Phe residue is replaced by another amino acid. Whether other
PP1-binding proteins contain Trp at this position, and the
signi¢cance of this variation, remain to be evaluated.
In the glycogen-targetting subunit of PP1 from skeletal
muscle, cyclic AMP-dependent protein kinase phosphorylates
the serine residue located between the Val and Phe residues of
the Val-Xaa-Phe motif. This disrupts the interaction with PP1
and is believed to be one of the mechanisms by which adre-
nalin stimulates glycogenolysis and inhibits glycogen synthesis
(reviewed in [1]). NIPP1 also contains phosphorylatable resi-
dues within the putative PP1-binding domain, and its ability
to suppress the activity of PP1 can be relieved by phospho-
rylation in vitro [12,15]. It is therefore intriguing that the
residue between the Val and Trp residues in p99 is Thr, while
a Ser residue lies immediately N-terminal to the Val. This
raises the possibility that the interaction of p99 and PP1 is
modulated by reversible phosphorylation of the p99 protein.
Preliminary data show that p99 is an RNA-binding protein,
which is consistent with the presence of multiple RGG boxes.
An ability to bind RNA, combined with the nuclear localisa-
tion pattern shown here, could be consistent with a role for
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Fig. 6. Disruption of the interaction between PP1 and p99 by syn-
thetic peptides containing PP1-binding motifs. A: PP1 activity was
measured in the presence of 5 nM p99 and indicated concentrations
of the peptide GKRTNLRKTGSERIAMGMRVKFNPLALLLDSC
(open circles, broken line) containing the putative PP1-binding site
from p53BP2 (underlined) or a control peptide REKPQT-
LPSAVKGD from a region of NIPP1 that does not interact with
PP1 (closed circles, full line). B: Same as A, except that the peptides
were from the putative PP1-binding region of p99 (residues 393^
408). The peptide corresponding to the wild-type sequence
(GRKRKSVTWPEEGKLR) is shown by the open circles and full
line, a peptide in which Trp401 was changed to Phe by the closed
diamonds and broken line, and a peptide in which Trp401 was
changed to Ala by the closed circles and dotted line. Data are
shown as mean þ S.E. for 3^6 experiments.
Fig. 5. E¡ect of full-length p99 (open circles, full line) and the frag-
ment encoded by EST-R11639 comprising residues 45^310 (closed
circles, broken line) on the phosphorylase phosphatase activity of
PP1Q. PP1 activity is plotted as a percentage of the activity observed
in the absence of both proteins. Data are shown as mean þ S.E. for
3^6 experiments.
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the p99-PP1 complex in regulating either RNA processing or
transport within the nucleus. Future experiments will focus on
identifying functional domains in the p99 protein and de¢ning
its role in regulating nuclear processes.
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